Insulin-like growth factor 1

Source: Wikipedia, the free encyclopedia.

IGF1
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl

ENSG00000017427

ENSMUSG00000020053

UniProt

P05019

P05017

RefSeq (mRNA)

NM_000618
NM_001111283
NM_001111284
NM_001111285

RefSeq (protein)

NP_000609
NP_001104753
NP_001104754
NP_001104755

NP_001104744
NP_001104745
NP_001104746
NP_001300939
NP_034642

Location (UCSC)Chr 12: 102.4 – 102.48 MbChr 10: 87.69 – 87.77 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Insulin-like growth factor 1 (IGF-1), also called somatomedin C, is a

molecular structure to insulin which plays an important role in childhood growth, and has anabolic effects in adults.[5]

In the 1950s IGF-1 was called "sulfation factor" because it stimulated sulfation of cartilage in vitro,[6] and in the 1970s due to its effects it was termed "nonsuppressible insulin-like activity" (NSILA).[7]

IGF-1 is a protein that in humans is encoded by the IGF1 gene.[8][9] IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges. IGF-1 has a molecular weight of 7,649 daltons.[10] In dogs, an ancient mutation in IGF1 is the primary cause of the toy phenotype.[11]

IGF-1 is produced primarily by the liver. Production is stimulated by growth hormone (GH). Most of IGF-1 is bound to one of 6 binding proteins (IGF-BP). IGFBP-1 is regulated by insulin. IGF-1 is produced throughout life; the highest rates of IGF-1 production occur during the pubertal growth spurt.[12] The lowest levels occur in infancy and old age.[13][14]

A synthetic analog of IGF-1,

growth failure in children with severe IGF-1 deficiency.[15]

Cyclic glycine-proline (cGP) is a metabolite of hormone insulin-like growth factor-1 (IGF-1). It has a cyclic structure, lipophilic nature, and is enzymatically stable which makes it a more favourable candidate for manipulating the binding-release process between IGF-1 and its binding protein, thereby normalising IGF-1 function.[16]

Synthesis and circulation

See also: Neurobiological effects of physical exercise § IGF-1 signaling

The

polypeptide hormone IGF-1 is synthesized primarily in the liver upon stimulation by growth hormone (GH). It is a key mediator of anabolic activities in numerous tissues and cells, such as growth hormone-stimulated growth, metabolism and protein translation.[17] Due to its participation in the GH-IGF-1 axis it contributes among other things to the maintenance of muscle strength, muscle mass, development of the skeleton and is a key factor in brain, eye and lung development during fetal development.[18]

A deficiency of IGF-1 is associated with the increased risks of

diabetes type 2, as well as cardiovascular morbidity and mortality.[17][19] Studies have shown the importance of the GH-IGF-1 axis in directing development and growth, where mice with a IGF-1 deficiency had a reduced body- and tissue mass. Mice with an excessive expression of IGF-1 had an increased mass.[19]

The levels of IGF-1 in the body vary throughout life, depending on age, where peaks of the hormone is generally observed during puberty and the

postnatal period. After puberty, when entering the third decade of life, there is a rapid decrease in IGF-1 levels due to the actions of GH. Between the third and eight decade of life, the IGF-1 levels decrease gradually, but unrelated to functional decline.[18] However, protein intake is proven to increase IGF-1 levels.[20]

3-d model of IGF-1

Mechanism of action

See also:
Hypothalamic–pituitary–somatic axis

IGF-1 is a primary mediator of the effects of

hematopoietic, and lung cells. In addition to the insulin-like effects, IGF-1 can also regulate cellular DNA synthesis.[21]

IGF-1 binds to at least two cell surface

AKT signaling pathway, a stimulator of cell growth and proliferation, and a potent inhibitor of programmed cell death .[22][23] The IGF-1 receptor and insuline receptor are two closely related members of a transmembrane tetrameric tyrosine kinase receptor family. They control vital brain functions, such as survival, growth, energy metabolism, longevity, neuroprotection and neuroregeneration.[24]

IGF-1 binds and activates its own receptor, IGF-1R, through the cell surface expression of Receptor Tyrosine Kinase's (RTK's), and further signals through multiple intracellular transduction cascades. IGF-1R is the critical role-playing inducer in modulating the metabolic effects of IGF-1 for cellular senescence and survival. At a localized target cell, IGF-1R elicits the mediation of paracrine activity. After its activation the initiation of intracellular signaling occurs inducing a magnitude of signaling pathways. An important mechanistic pathway involved in mediating a cascade affect regulated by phosphatidylinositol-3 kinase (PI3K) and its downstream partner, mTOR (mammalian Target of Rapamycin). Rapamycin binds with the enzyme FKBPP12 to inhibit the mTORC1 complex. mTORC2 remains unaffected and responds by up-regulating AKT, driving signals through the inhibited mTORC1. Phosphorylation of Eukaryotic translation initiation factor 4E (EIF4E) by mTOR suppresses the capacity of Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) to inhibit EIF4E and slow metabolism.[25][26] A mutation in the signaling pathway PI3K-AKT-mTOR is a big factor in the formation of tumors found predominantly on skin, internal organs, and secondary lymph nodes (Kaposi sarcoma).[26]

Metabolic effects

As a major growth factor, IGF-1 is responsible for stimulating growth of all cell types, and causing significant metabolic effects.[27] One important metabolic effect of IGF-1 is its ability to signal cells that sufficient nutrients are available for cells to undergo hypertrophy and cell division.[28] These signals also enable IGF-1 to inhibit cell apoptosis and increase the production of cellular proteins.[28] IGF-1 receptors are ubiquitous, which allows for metabolic changes caused by IGF-1 to occur in all cell types.[27] IGF-1's metabolic effects are far-reaching and can coordinate protein, carbohydrate, and fat metabolism in a variety of different cell types.[27] The regulation of IGF-1's metabolic effects on target tissues is also coordinated with other hormones such as growth hormone and insulin.[29]

Related growth factors

IGF-1 exists within the insulin/insulin-like growth factor (IGF) signaling system. The system consists of three ligands (

IGF-1R receptor) and six ligand binding proteins (IGFBP 1-6).[30] It plays an essential role in proliferation, survival, regulation of cell growth and affects almost every organ system in the body.[31]

Similarly to IGF-1,

IGF-2 is mainly produced in the liver. After release into circulation it stimulates growth and cell proliferation. IGF-2 is thought to be a fetal growth factor, as it is essential for a normal embryonic development and is highly expressed in embryonic and neonatal tissues.[32]

A

splice variant of IGF-1 sharing an identical mature region, but with a different E domain is known as mechano-growth factor (MGF).[33]

Disorders

Laron syndrome

Patients with severe primary insulin-like growth factor-1 deficiency (IGFD), called

growth failure.[34]

Laron syndrome does not respond at all to

growth hormone treatment due to a lack of GH receptors. The FDA has grouped these diseases into a disorder called severe primary IGF deficiency. Patients with severe primary IGFD typically present with normal to high GH levels, height below 3 standard deviations (SD), and IGF-1 levels below 3 SD.[35] Severe primary IGFD includes patients with mutations in the GH receptor, post-receptor mutations or IGF mutations, as previously described. As a result, these patients cannot be expected to respond to GH treatment.[36]

People with Laron syndrome have very low rates of both cancer and diabetes.[37]

Acromegaly

somatotrophs). It leads to anatomical changes and metabolic dysfunction caused by both an elevated GH and elevated IGF-1 levels.[38]

High level of IGF-1 in acromegaly is related to an increased risk of some cancers, particularly colon cancer and thyroid cancer.[39]

Use as a diagnostic test

IGF-1 levels can be analyzed and used by physicians as a

screening test for growth hormone deficiency, acromegaly and gigantism.[35] However IGF-1 was proved to be a bad diagnostic screening test for growth hormone deficiency (GHD). Therefore, IGF-1 should not be used alone as a screening test for GHD.[40]

The ratio of IGF-1 and insulin-like growth factor 1 binding protein-3 (IGFBP-3) can be analyzed and used as a diagnostic tool for growth-hormone related disorders.[41]

Interpretation of IGF-1 levels is complicated by the wide normal ranges, and marked variations by age, sex, and pubertal stage. Clinically significant conditions and changes may be masked by the wide normal ranges. Sequential measurement over time is often useful for the management of several types of pituitary disease, undernutrition, and growth problems.[42]

Causes of elevated IGF-1 levels

Health effects

Cancer

Several studies have shown associations between high levels of IGF-1 and an increased risk of tumor development. With an increase in serum IGF-1 levels of 100 ng/ml, there was a corresponding increase in the risk of colorectal cancer with 69%. High levels of IGF-1 were also associated with a 65% risk increase in breast cancer, 49% increase in prostate cancer and 106% in lung cancer.[48]

It has been suggested that consumption of IGF-1 in dairy products could increase cancer risk, particularly prostate cancer.[49][50] However, a 2018 review by the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC) concluded that there is "insufficient evidence to draw any firm conclusions as to whether exposure to dietary IGF-1 is associated with an increased incidence of cancer in consumers".[50] Certain dairy processes such as fermentation are known to significantly decrease IGF-1 concentrations.[51]

A mutation in the signaling pathway PI3K-AKT-mTOR is a factor in the formation of tumors found predominantly on skin, internal organs, and secondary lymph nodes (Kaposi sarcoma).[52]

Diabetes

Low IGF-1 levels are shown to increase the risk of developing type 2 diabetes and insulin resistance.[53] On the other hand, a high IGF-1 bioavailability in diabetes patients may delay or prevent the inception of diabetes-associated complications. A normal functioning IGF-1 mechanism reduces the occurrence of diabetes complications associated with lower IGF-1 levels, as it improves impaired small blood vessel function.[54]

Mortality

A 2022 review found that both high and low levels of IGF‐1 increase mortality risk, whilst a mid‐range (120–160 ng/ml) is associated with the lowest mortality.[48]

Other

Increased IGF-1 levels are associated with a lower risk of

ischaemic stroke.[55][56][57]

Clinical trials

Mecasermin

Mecasermin is a complex consisting of recombinant human IGF-1 and recombinant human IGF-binding protein-3.[58] The complex is used for the long-term treatment in children with growth failure, where they suffer from severe IGF-1 deficiency unresponsive to GH. Children with growth failure were given 0,12 mg/kg subcutaneous mecasermin two times a day over a period with a mean duration of 4,4 years (range: 0,04-12,5 years). During the first year of treatment the height velocity of the children increased from a mean of 2,8 cm/year at baseline to a mean of 8,0 cm/year. The mean growth velocities continued to remain above baseline for up to 8 years.[59]

Mecasermin therapy is also shown to be beneficial with other conditions including diabetes mellitus and anorexia nervosa.[59]

rhIGF-1

Several companies have evaluated administering recombinant human IGF-1 (rhIGF-1) in clinical trials for type 1 diabetes. These patients, despite having increased GH secretion, have low levels of circulating IGF-1 and therefore may benefit from rhIGF-1 therapy.[60] Results shows that a rhIGF-1 therapy two times a day in adults with type 1 diabetes increased the circulating IGF-1. This was with a reciprocal decrease in IGF-2 and an elevation of IGFBP-2.[60]

See also

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000017427 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000020053 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. PMID 23382729
    .
  6. PMID 13429201
    .
  7. PMID 640301
    .
  8. S2CID 5825276
    .
  9. S2CID 4336584
    .
  10. PMID 632300
    .
  11. S2CID 246359754
    .
  12. PMID 28076448
    .
  13. S2CID 6965802
    .
  14. S2CID 24346368
    .
  15. PMID 18481900
    .
  16. PMID 36770687
    .
  17. ^
    PMID 32548700
    .
  18. ^
    ISSN 1018-3647
    .
  19. ^
    S2CID 163168020
    .
  20. PMID 24606898
    .
  21. PMID 12235108
    .
  22. PMID 10490655
    .
  23. PMID 10364155
    .
  24. S2CID 14265087
    .
  25. PMID 23708663
    .
  26. ^
    PMID 30894372
    .
  27. ^
    PMID 22682639
    .
  28. ^
    PMID 26453498
    .
  29. PMID 14702105
    .
  30. PMID 34680948
    .
  31. S2CID 24843614
    .
  32. ISBN 978-0-12-370879-3
    . GF-II appears to be essential for normal embryonic development and, as such, IGF-II is thought to be a fetal growth factor. IGF-II is highly expressed in embryonic and neonatal tissues and promotes proliferation of many cell types primarily of fetal origin.
  33. PMID 17581790
    .
  34. S2CID 23165648
    .
  35. ^
    PMID 25470569
    .
  36. PMID 24639006
    .
  37. PMID 21325617
    .
  38. ^
    PMID 24566817
    .
  39. PMID 30197531
    .
  40. PMID 34373538
    .
  41. PMID 36251796
    .
  42. PMID 38044875
    .
  43. PMID 24606898
    .
  44. PMID 21699736
    .
  45. PMID 20862389
    .
  46. ^
    PMID 19226264
    .
  47. PMID 19766843
    .
  48. ^
    PMID 35048526
    .
  49. PMID 28361446
    .
  50. ^ a b "Statement on possible carcinogenic hazard to consumers from insulin-like growth factor-1 (IGF-1) in the diet" (PDF). assets.publishing.service.gov.uk. Retrieved 4 February 2023.
  51. PMID 28544872
    .
  52. PMID 30894372
    .
  53. PMID 33905470
    .
  54. PMID 33905470
    .
  55. PMID 30735831
    .
  56. S2CID 248924624
    .
  57. PMID 35705353
    .
  58. S2CID 262107214
    . Mecasermin is a complex of recombinant human IGF-1 and recombinant human IGF-binding protein-3 (rhIGFBP-3) used to treat children with severe IGF-1 deficiency unresponsive to GH.
  59. ^
    PMID 18481900
    .
  60. ^
    S2CID 20727527
    .

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Insulin-like_growth_factor_1&oldid=1213321134"